Semaglutide: The truth behind Wegovy, Alzheimer’s, and what no influencer will tell you

If you’ve been keeping an eye on health trends, or simply walked past a pharmacy in the last few months, you’ve surely heard about semaglutide. It’s that complicated-sounding name everyone associates with the famous weight-loss pen, but believe me, the story goes far beyond mirror selfies or the miracle prescriptions we see on social media. As someone who’s covered the pharmaceutical sector for years, I’m going to tell you what’s really going on, especially after data was leaked at international conferences that gave the conversation an unexpected twist.

The boom of the famous "pen" and what it hides

The arrival of drugs like Wegovy and Ozempic revolutionised how we view diabetes and obesity treatment. On the streets of London or Manchester, it’s not unusual to hear someone asking for Wegovy 0.25mg, that specific presentation which comes in a box with an applicator system pre-filled with 1.5mL of subcutaneous solution plus 4 Novofine Plus needles. It’s the starter format, the one many seek out to begin treatment. But here’s the first hard truth: this isn’t a toy. When I see that semaglutide being sold as the magic solution to lose five kilos in a month without breaking a sweat, it makes my hair stand on end. Because it’s a potent drug, and like any potent drug, it comes with rules.

The news no one saw coming: A farewell to hope against Alzheimer’s?

A few months ago, the scientific community was buzzing with excitement. There was a genuine hope that semaglutide wouldn’t just help with weight or glucose, but could also act as a shield against Alzheimer’s. There was talk of studies suggesting a neuroprotective effect, that it could halt cognitive decline. It seemed like finding an extra benefit in something that was already working. However, as in life, reality has just given us a rude awakening.

Just a few weeks ago, during the conclusion of the phase III clinical trials we were all eagerly awaiting, the finding was clear: semaglutide failed to slow the progression of mild Alzheimer’s. It pained me to read the internal report, because I know that many families in the UK, caring for loved ones with this disease, had pinned their hopes on this. The data, which we handled carefully within the industry, showed that while the drug works wonders on metabolism, when it comes to memory loss and cognitive function, there was simply no significant difference between those taking the drug and those on a placebo. It’s a full stop for one of the most exciting hypotheses put forward in recent years.

What you should know if you’re already using semaglutide

That it doesn’t work for Alzheimer’s doesn’t detract from its effectiveness for what it was approved for. But this is where I want to be serious with you, because in my experience, people tend to skip steps. If you’re considering using Wegovy 0.25mg or any presentation, bear this in mind:

• It’s not for everyone: The initial 0.25mg presentation is designed to let your body adapt. Skipping doses or starting with a higher one could land you straight in hospital with pancreatitis.
• The applicator system isn’t optional: That “pre-filled applicator system with 1.5mL subcutaneous solution” isn’t just for show. The method of administration and the Novofine Plus needles are designed to minimise pain and ensure the dose is correct.
• It’s a treatment, not a one-month fad: Semaglutide works while you’re using it. I’ve seen cases of people using it for an event and then stopping, only to regain the weight and more. This is a long-term commitment, if your doctor deems it necessary.

The "UK" factor and the grey market

Here in the UK, we have a particular relationship with medication. We’re prone to self-prescribing and the famous "just give me a little bit". With semaglutide, this has been chaotic. I’ve seen WhatsApp groups sharing sellers offering "generic Wegovy" or the "for diabetics" version as if they were sweets. I’m telling you this with the confidence of someone who has seen both sides of the coin: don’t take the risk. The Novofine Plus needles that come in the official box aren’t a luxury; they’re part of a safety protocol. Buying this on the black market is playing Russian roulette with your health.

The failure of the studies to halt Alzheimer’s isn’t bad news in itself, but rather an invitation to get our feet back on the ground. Science advances, sometimes with setbacks, but it keeps advancing. Semaglutide is an incredibly useful tool for those who truly need it under medical supervision. For everyone else, the lesson is clear: don’t look for shortcuts, especially when it comes to your brain and your wellbeing. If your doctor prescribed it, trust the process, respect the doses and that subcutaneous applicator system. If you only want it because it’s trendy, perhaps now is the time to sit and think about whether it’s worth playing with fire.